Radiation Oncology Market (2025 - 2030) Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By Technology, By Application, By Region, And Segment Forecasts

Radiation Oncology Market Summary

The global radiation oncology market size was estimated at USD 10.56 billion in 2024 and is projected to reach USD 21.19 billion by 2030, growing at a CAGR of 11.2% from 2025 to 2030. Key factors driving the market include technological advancements in radiotherapy equipment, the global rise in cancer cases, and increasing adoption of radiation therapy in oncology treatment.

Recently, in March 2025, Actinium Pharmaceuticals announced the launch of ATNM-400, an innovative radiotherapy for prostate cancer that targets non-prostate-specific membrane antigen (PSMA) pathways. The therapy utilizes the alpha-emitting radioisotope actinium-225 (Ac-225) to deliver targeted radiation treatment.

Furthermore, the radiation oncology industry is witnessing increased demand for radiotherapy due to the rising global cancer burden. According to the WHO, globally, around 19.3 million people were suffering from cancer, and 10 million died from it in 2022. Moreover, WHO in Europe estimated that there were 4.6 million new people diagnosed with various indications of cancers, such as prostate, breast, lung, colorectal, and brain, and around 2.1 million people across European countries died from the disease in 2020. As per the American Cancer Society’s 2022 report, breast cancer is the most common occurring condition, which accounts for approximately 351,400 new cases in the U.S. of invasive and non-invasive breast tumors, respectively.

In the dynamic market outlook of the radiation therapy space, key players are making strategic moves to enhance their market presence. In October 2023, Accuray Incorporated gained approval for its Tomo C radiation therapy system in China, opening new avenues for growth in the region. This regulatory milestone reflects Accuray's commitment to expanding its market reach. Similarly, in June 2023, PharmaLogic Holdings Corp. entered into a Master Services Agreement for the development and production of theranostic candidates VMT-01 and VMT-NET. These radiopharmaceuticals, currently in the research and development phase, aim to address the diagnostic and treatment needs of metastatic melanoma and neuroendocrine cancers. This strategic collaboration underscores PharmaLogic's dedication to advancing innovative solutions in the oncology space.

Market Concentration & Characteristics

The market growth stage is high, at an accelerating rate of pace. The radiation therapeutic in oncology is characterized by a high degree of innovation. This can be attributed to advanced technologies and methodologies for transforming treatment practice. The market witnesses notable M&A activities by the leading players. Leading players are strategically joining forces to expand and enhance their services, gain access to new technologies, consolidate the rapidly growing market, and address the increasing strategic importance of radiotherapy.

In the radiation oncology industry, key player IBA has taken a significant step in July 2023 by partnering with Apollo Proton Cancer Centre in India. This collaboration aims to enhance the skills of oncologists in proton beam therapy through specialized training programs. This strategic move by IBA underscores the growing importance of knowledge-sharing and skill development within the radiation oncology sector. The initiative is expected to contribute to the overall advancement of proton therapy applications, potentially impacting the market dynamics positively. As a result, other industry players might consider similar partnerships or training programs to stay competitive and contribute to the overall growth and improvement of radiation oncology practices.

The market is also subject to increasing regulatory scrutiny. Radiation exposure is regulated by governmental agencies such as the FDA, the Department of Transportation (DOT), the Environmental Protection Agency (EPA), and the Nuclear Regulatory Commission (NRC). Radiation-emitting devices used in medicine are regulated by the Center for Devices and Radiologic Health (CDRH), whereas the use of radiation for medical purposes is regulated by the FDA. Radiation oncology devices are governed under the Radiation Control for Health and Safety Act, 1968. 

The Code of Federal Regulations Title 21 governs the use of radiopharmaceuticals in the U.S. The diagnostic and therapeutic applications of radiopharmaceuticals are separately covered under this title in Part 315 & Part 361, respectively. In addition, the Nuclear Regulatory Commission (NRC) regulates the use of radiopharmaceuticals in 37 states. The NRC authorizes utilization and possession of radioactive source material, by product material, and special nuclear material.

CDRH governs the use of radiopharmaceuticals. In addition, it governs the use of electron-emitting products, including medical devices. However, radioisotopes that produce chemical effects, such as Ra-223, are governed by the Center for Drug Evaluation & Research, and the ones considered biologics, such as I-131 and Y-90, are used for the treatment of non-Hodgkin’s lymphoma and are governed by the Center for Biologics Evaluation and Research. 

Radiation therapy has significant substitutes like surgeries and chemotherapy that improve many of the anticancer effects, but have more side effects. However, any technological advancements in radiation therapy that offer improved technology with high efficacy may be a threat to existing treatment options, such as IGRT, proton therapy, and 3D-conformity therapy, encouraging patients to shift to advanced treatment options. The lack of effective treatment options for complex cancers and increased side effects of therapies are expected to negatively impact the overall market growth.

Moreover, the industry is witnessing a growing number of geographical expansion strategies, for instance, players such as Curium in June 2021, acquired Austrin to expand its presence in Europe for its broad portfolio of life-saving diagnostic solutions. This acquisition will help the company strengthen its positron emission-tomography (PET) radiopharmaceutical business.

Type Insights

The external beam radiation therapy (EBRT) market, which includes linear accelerators (Linac), and compact advanced radiotherapy systems, dominated the overall market with the largest revenue share in 2024 due to increased adoption in the treatment of various types of cancers. Furthermore, EBRT products have a high ability to kill tumors in the early phases as compared to conventional therapies with fewer side effects. Moreover, rapid technological advancements and investigation of such technologies on various cancer treatments are increasing demand for LINACs and MR-LINACs, thereby contributing to the growth of the market.

Linear accelerator (Linac) uses microwave technology like radar to destroy tumor cells by delivering high-energy electrons or X-rays near the tumor region and sparing the surrounding healthy tissue. Introduction of novel linear accelerators contributes to market growth. For instance, in May 2024, Elekta announced the launch of Evo, its latest linear accelerator (linac) system. Evo features advanced high-definition, AI-enhanced imaging and is designed to support both offline and online adaptive radiation therapy, as well as enhanced standard image-guided radiation treatments. This versatile CT-Linac enables clinicians to tailor radiation therapy techniques to meet each patient's specific needs. Elekta introduced Evo at ESTRO 2024, Europe’s largest radiation oncology industry exhibition, held in Glasgow, Scotland, during the Annual Congress of the European Society for Radiotherapy and Oncology. 

Technology Insights

The IMRT segment held the largest revenue share of 24.06% in 2024, attributed to the substantial demand for treatment and increased availability of technologically advanced intensity-modulated radiotherapy (IMRT) in countries with unmet treatment needs. However, brachytherapy is estimated to be the fastest-growing segment over the forecast period due to the benefits associated with its high adoption rate and minimal risk of side effects.

3D-CRT projects radiation beams in such a way that the beams match the dimensions of the tumor and help physicians to know the exact dimensions of the tumor, which limits the damage to healthy tissues. It allows delivery of higher dose levels at the tumor site, thereby increasing its effectiveness to shrink and destroy the tumor by using a multi-leaf collimator (MLC) in a step-and-shoot technique. 3D-CRT is used to treat head & neck, liver cancer, prostate, lung, and brain cancer.

The advancements in brachytherapy provide precise and targeted dose delivery and personalized treatment options to patients. This technology is mostly used for the treatment of prostate cancer. Compared to conventional treatment techniques, its improved efficacy and reduced setup time are likely to drive the worldwide brachytherapy segment. Moreover, supportive reimbursement policies for products related to brachytherapy reduced the treatment cost, thereby encouraging patients to avail treatment. In February 2025, the Saskatchewan Cancer Agency (SCA) announced the launch of its Interstitial High-Dose-Rate (HDR) Gynecological Brachytherapy program, a specialized and highly targeted form of radiation therapy considered the gold standard for treating cervical cancer. With this program now available in Saskatchewan, patients no longer need to travel out of province to access this advanced treatment.

Application Insights

The EBRT segment for prostate cancer held the largest revenue share of 58.65% in 2024 and is anticipated to maintain its dominance over the forecast period. This can be attributed to the rising global cancer prevalence and increasing adoption of EBRT systems by cancer centers and hospitals. For instance, in September 2021, Unicancer acquired multiple Radixact Systems of Accuray, Inc. with ClearRT with an aim to provide personalized treatment to patients in Europe. Unicancer is a French hospital network that provides treatment to 530,000 cancer patients annually.

The market for IBRT is anticipated to witness significant growth over the forecast period due to the growing prevalence of cancer in developing countries and increased product penetration. IBRT is mostly used in conjunction with breast cancer surgery. Brachytherapy for breast tumors involves different techniques for placing devices, such as interstitial brachytherapy and intracavitary brachytherapy. The most performed technique for breast cancer is intracavitary brachytherapy. According to a study published by the National Cancer Institute (NCI) showed that whole breast irradiation (WBI) and accelerated partial-breast irradiation (APBI) lower the rate of cancer recurring in breast cancer patients.IMRT has become the standard treatment for locally advanced head and neck cancer due to its high conformality. Moreover, gynecologic cancer is mostly treated with the help of various brachytherapy techniques.

Regional Insights

North America radiation oncology industry dominated globally in terms of revenue share of 47.16% in 2024, owing to the favorable government initiatives and availability of technologically advanced radiotherapy equipment. Furthermore, active participation of key players to increase their market share in region is fueling the market growth. For instance, in December 2021, MVision AI entered partnership with Medron Medical Systems to distribute AI radiotherapy technology of MVision in Canada. The use of AI technology provides high accuracy, leading to improved patient outcomes.

U.S. Radiation Oncology Market Trends

The radiation oncology industry in the U.S. benefits from strong technological innovation, high healthcare spending, and well-established cancer treatment infrastructure. Widespread adoption of advanced modalities like proton therapy and image-guided radiotherapy (IGRT) fuels demand. In addition, a rising geriatric population, increasing cancer incidence, and supportive reimbursement policies by Medicare and private insurers significantly contribute to market expansion. Active R&D and frequent clinical trials further enhance treatment precision and accessibility, making the U.S. a global leader in radiation oncology.

Europe Radiation Oncology Market Trends

The radiation oncology industry in Europe is driven by universal healthcare access, rising cancer prevalence, and government funding in public hospitals. Countries are investing in upgrading linear accelerators and integrating AI into radiotherapy workflows. EU-wide collaborations in oncology research promote innovation and early technology adoption. Public awareness campaigns and national screening programs further increase early diagnosis rates, boosting demand for radiation therapy. Integration of radiology networks across borders also improves access and standardization of cancer care.

The UK radiation oncology industry is growing due to NHS investments in cancer treatment infrastructure, including modernizing radiotherapy equipment. Government-backed initiatives like the Cancer Strategy emphasize early detection and rapid access to treatment. High incidence of breast and lung cancer, paired with centralized radiology networks, supports demand for radiotherapy. Integration of AI and adaptive radiotherapy, along with strong clinical trial participation, also bolsters innovation and adoption of cutting-edge technologies across NHS trusts.

Germany’s radiation oncology industry growth is driven by its robust healthcare system, widespread access to cancer care, and heavy investment in medical technology. High per capita healthcare expenditure and a strong manufacturing base support local development and deployment of advanced radiation systems. In addition, Germany’s aging population, coupled with increasing cancer diagnoses, drives treatment demand. Public-private partnerships in oncology research and continuous upgrades in treatment planning and delivery systems fuel market expansion in this technologically advanced nation.

Asia Pacific Radiation Oncology Market Trends

Asia Pacific radiation oncology industry is projected to be the fastest-growing globally over the forecast period due to improvements in healthcare infrastructure, increase in patient awareness levels, and high unmet patient needs. In addition, rising cancer burden and funding support to major players in the region are expected to offer lucrative opportunity for segment growth. According to Globocan report 2020, about 9.5 million new cancer cases were diagnosed, and 5.8 million died due to this disease in the region, increasing demand for radiotherapy to manage the impact of cancer in the countries.

China radiation oncology industry is expanding rapidly due to a rising cancer burden, large population base, and government efforts to improve oncology infrastructure. The Healthy China 2030 initiative supports investment in radiotherapy centers and training of oncologists. Urbanization and healthcare reforms have improved access to treatment. Domestic companies are also emerging with cost-effective radiotherapy solutions. Increased adoption of intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reflects technological progress and rising clinical standards.

Japan radiation oncology industry growth stems from a high elderly population, advanced medical infrastructure, and early adoption of precision radiotherapy technologies. Proton therapy is well-established and heavy government investment in cancer research accelerates development. Favorable reimbursement for advanced treatments and public awareness of early cancer detection drive clinical demand. In addition, collaboration between academia and industry supports innovation, while national health insurance ensures widespread access to sophisticated radiation oncology services.

Latin America Radiation Oncology Market Trends

Latin America radiation oncology industry growth is driven by rising cancer incidence, improving healthcare infrastructure, and growing public-private investment in cancer treatment. Countries like Brazil and Mexico are expanding radiotherapy centers and increasing access to IMRT and 3D conformal radiotherapy. International collaborations and training programs are improving clinical capabilities. Though limited by healthcare disparities, increased awareness and access to insurance are expanding patient access to radiation therapy across the region.

MEA Radiation Oncology Market Trends

The Middle East and Africa (MEA) radiation oncology industry is witnessing growth due to government investments in healthcare modernization and an increasing focus on oncology. Gulf countries like the UAE and Saudi Arabia are establishing state-of-the-art cancer centers, while Africa is seeing support from international NGOs and partnerships. Rising cancer awareness, urbanization, and expansion of private healthcare are improving access to radiation services. However, growth is uneven, with more rapid development in wealthier nations.

Key Radiation Oncology Company Insights

The leading players in radiation oncology industry are focusing on growth strategies, such as innovations with radiotherapy, product launches, and mergers & acquisitions. For instance, in June 2022, a company pioneering the use of biology-guided radiotherapy (BgRT), RefleXion Medical announced its first symposium focused on the power of using cancer biology to direct treatment planning and delivery for personalized radiotherapy. Moreover, in October 2021, Siemens Healthineers AG in collaboration with UC Health Proton Therapy Center completed enrollment for FAST-01 of Flash Therapy for the treatment of symptomatic bone metastases.

Recent Development

• In April 2025, ZEISS Medical Technology reaffirmed its commitment to advancing modern oncology with the FDA’s 510(k) clearance of its INTRABEAM 700 system. This next-generation platform delivers robotic-assisted precision for intraoperative radiation therapy (IORT). Featuring a digital-first design, the INTRABEAM 700 streamlines workflows and enhances connectivity-delivering significant clinical value in neuro-oncology and breast cancer treatment.

• In March 2024, AstraZeneca announced a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing next-generation radioconjugates (RCs). This acquisition represents a significant advancement in AstraZeneca’s mission to revolutionize cancer care by shifting from traditional therapies such as chemotherapy and radiotherapy to more precise, targeted treatment approaches.

• In February 2023, RefleXion Medical, a therapeutic oncology company, announced that the U.S. Food and Drug Administration (FDA) granted the first marketing clearance for its SCINTIX biology-guided radiotherapy-a groundbreaking treatment designed for both early- and late-stage cancers. To highlight the significance of this advancement, the company will host a live-streamed event featuring its co-founder and CEO, who will discuss the impact of SCINTIX therapy on cancer care.

Radiation Oncology Market Report Scope

Global Radiation Oncology Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global radiation oncology market report based on type, technology, application, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • External Beam Radiation Therapy

    • Linear Accelerators (Linac)

    • Compact advanced radiotherapy systems

      • Cyberknife

      • Gamma Knife

      • Tomotherapy

    • Proton Therapy

      • Cyclotron

      • Synchrotron

  • Internal Beam Radiation Therapy

    • Brachytherapy

      • Seeds

      • Applicators and Afterloaders

      • Electronic Brachytherapy

    • Systemic Beam Radiation Therapy

    • Others

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • External Beam Radiation Therapy

    • Image-Guided Radiotherapy (IGRT)

    • Intensity Modulated Radiotherapy (IMRT)

    • Stereotactic Technology

    • Proton Beam Therapy

    • 3D Conformal Radiotherapy (3D CRT)

    • Volumetric Modulated Arc Therapy (VMAT)

  • Brachytherapy

    • Low-Dose Rate Brachytherapy

    • High-Dose Rate Brachytherapy

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • External Beam Radiation Therapy

    • Prostate Cancer

    • Breast Cancer

    • Lung Cancer

    • Head and Neck Cancer

    • Colorectal Cancer

    • Others

  • Internal Beam Radiation Therapy

    • Prostate Cancer

    • Gynecological Cancer

    • Cervical Cancer

    • Breast Cancer

    • Penile Cancer

    • Others

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Rest of Europe

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Thailand

    • Rest of APAC

  • Latin America

    • Brazil

    • Argentina

    • Rest of LATAM

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA